Fourth time's the charm? blue­bird picks up new fi­nance chief; New CEOs here and there

→ blue­bird bio has been able to cinch two FDA OKs, one for Zyn­te­glo and the oth­er for Skysona, in quick suc­ces­sion, but has had trou­ble hold­ing on­to a CFO. In steps Chris Krawtschuk, who’ll pick up where Ja­son Cole left off as he hit the ex­it. Krawtschuk’s been CFO at Ju­bi­lant Phar­ma and Mor­phoSys and was VP, lead di­vi­sion­al con­troller at Pfiz­er. Krawtschuk marks the com­pa­ny’s third CFO just this year — af­ter Cole took over for Gi­na Con­syl­man, who left for Vedere Bio II — and is left to help steer the com­pa­ny as it be­gins sales of its near­ly $3 mil­lion gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER